Saliogen Therapeutics Closes $115 Million Oversubscribed Series B Financing To Advance Gene Coding™ – A New Category Of Genetic Medicine
Jan 05, 2022•almost 4 years ago
Amount Raised
$115 Million
Round Type
series b
CambridgeDescription
SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech